7:13 PM
Jun 26, 2007
 |  BC Extra  |  Top Story

Nuvelo, Bayer end alfimeprase deal

NUVO said it and Bayer (FSE:BAY; BAY) will end a January 2006 deal to develop NUVO's alfimeprase, effective June 30. Last December, the thrombolytic agent missed the primary endpoints in a pair of Phase III trials: NAPA-2 for acute peripheral arterial...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >